PAtient RegisTry Assessing Effectiveness and Safety of HEart Failure treatmeNt With LCZ696 acrOss CaNada
Phase of Trial: Phase IV
Latest Information Update: 29 May 2018
At a glance
- Drugs Sacubitril/valsartan (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- Acronyms PARTHENON
- Sponsors Novartis Pharmaceuticals
- 23 May 2018 Planned End Date changed from 1 May 2021 to 12 Oct 2020.
- 23 May 2018 Planned primary completion date changed from 1 May 2021 to 12 Oct 2020.
- 10 Jun 2017 Biomarkers information updated